Cited by 838Immunotherapy and Immune ResponsesImmune Response and InflammationCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

Open access

Chiba, Shigeki, Baghdadi, Muhammad, Akiba, Hisaya, Yoshiyama, Hironori, Kinoshita, Ichiro, Dosaka-Akita, Hirotoshi, Fujioka, Yoichiro, Ohba, Yusuke, Gorman, Jacob V, Colgan, John D, Hirashima, Mitsuomi, Uede, Toshimitsu, Takaoka, Akinori, Yagita, Hideo, Jinushi, Masahisa·2012·Nature Immunology

DOI 10.1038/ni.2376PMC PMC3622453

Open this paper in CoChat — free account

Abstract

The mechanisms by which tumor microenvironments modulate nucleic acid-mediated innate immunity remain unknown. Here we identify the receptor TIM-3 as key in circumventing the stimulatory effects of nucleic acids in tumor immunity. Tumor-associated dendritic cells (DCs) in mouse tumors and patients with cancer had high expression of TIM-3. DC-derived TIM-3 suppressed innate immune responses through the recognition of nucleic acids by Toll-like receptors and cytosolic sensors via a galectin-9-independent mechanism. In contrast, TIM-3 interacted with the alarmin HMGB1 to interfere with the recruitment of nucleic acids into DC endosomes and attenuated the therapeutic efficacy of DNA vaccination and chemotherapy by diminishing the immunogenicity of nucleic acids released from dying tumor cells. Our findings define a mechanism whereby tumor microenvironments suppress antitumor immunity mediated by nucleic acids.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/ni.2376

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Taking dendritic cells into medicine
Steinman, R. M., & Banchereau, J. (2007) · Nature · doi:10.1038/nature06175 · Cited by 2,162
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,747
HMGB1 is a therapeutic target for sterile inflammation and infection
Andersson, U., & Tracey, K. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101323 · Cited by 1,437

Flagged first, then by citations

Show all 50 references

Sorted by citations

Items 301–400 of 838

Role of Tim-3 in hepatitis B virus infection: An overview
Liu, Y., Gao, L., Liang, X., & Ma, C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i7.2294 · Cited by 46
Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells
Zhao, S., Wang, C., Lu, P., Lou, Y., Liu, H., Wang, T., Yang, S., Bao, Z., Han, L. G., Liang, X., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003176 · Cited by 46
High mobility group box 1 (HMGB1) acts as an “alarmin” to promote acute myeloid leukaemia progression
Yasinska, I. M., Silva, I. G., Sakhnevych, S. S., Rüegg, L., Hussain, R., Siligardi, G., Fiedler, W., Wellbrock, J., Bardelli, M., Varani, L., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1438109 · Cited by 45
Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases
Zhai, Y., Moosavi, R., & Chen, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645699 · Cited by 46
The Intestinal Commensal, Bacteroides fragilis, Modulates Host Responses to Viral Infection and Therapy: Lessons for Exploration during Mycobacterium tuberculosis Infection
Eribo, O. A., du Plessis, N., & Chegou, N. N. (2021) · Infection and Immunity · doi:10.1128/iai.00321-21 · Cited by 45
Impact of immune cells on the hallmarks of cancer: A literature review
Costa, A. C., Santos, J., da Costa, R. M. G., & Medeiros, R. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103541 · Cited by 48
Taming Dendritic Cells with TIM-3: Another Immunosuppressive Strategy Used by Tumors
Patel, J. M., Bozeman, E. N., & Selvaraj, P. (2012) · Immunotherapy · doi:10.2217/imt.12.126 · Cited by 45
Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia
Kikushige, Y., & Miyamoto, T. (2015) · Oncology · doi:10.1159/000431062 · Cited by 48
Integrated Nanovaccine with MicroRNA-148a Inhibition Reprograms Tumor-Associated Dendritic Cells by Modulating miR-148a/DNMT1/SOCS1 Axis
Liu, L., Yi, H., Wang, C., He, H., Li, P., Pan, H., Sheng, N., Ji, M., Cai, L., & Ma, Y. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600182 · Cited by 45
Novel immune checkpoint targets: A promising therapy for cancer treatments
Patwekar, M. F., Sehar, N., Patwekar, F., Medikeri, A., Ali, S., Aldossri, R. M., & Rehman, M. U. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111186 · Cited by 44
Interplay between dendritic cells and cancer cells
Martínek, J., Wu, T.-C., Cadena, D., Banchereau, J., & Palucka, K. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.07.008 · Cited by 45
Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy
Devillier, R., Chrétien, A.-S., Pagliardini, T., Salem, N., Blaise, D., & Olive, D. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0920-198rr · Cited by 49
Targeting NK Cells to Enhance Melanoma Response to Immunotherapies
Lee, H., da Silva, I. P., Palendira, U., Scolyer, R. A., Long, G. V., & Wilmott, J. S. (2021) · Cancers · doi:10.3390/cancers13061363 · Cited by 45
HMGB1 is a promising therapeutic target for acute liver failure
Yamamoto, T., & Tajima, Y. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1345625 · Cited by 43
Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination
Zhou, Z., Mai, Y., Zhang, G., Wang, Y., Sun, P., Jing, Z., Li, Z., Xu, Y., Han, B. R., & Liu, J. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217079 · Cited by 45
Toll-like receptor 4 signaling: A common pathway for interactions between prooxidants and extracellular disulfide high mobility group box 1 (HMGB1) protein-coupled activation
Zhang, Y., Karki, R., & Igwe, O. J. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.08.109 · Cited by 42
Tim-3 inhibits macrophage control of Listeria monocytogenes by inhibiting Nrf2
Wang, Z., Sun, D., Chen, G., Li, G., Dou, S., Wang, R., He, X., Hou, C., Li, Y., Feng, J., et al. (2017) · Scientific Reports · doi:10.1038/srep42095 · Cited by 42
Leukemia-induced dysfunctional TIM-3+CD4+ bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients
Blaeschke, F., Willier, S. M., Stenger, D., Lepenies, M., Horstmann, M. A., Escherich, G., Zimmermann, M., Ringeling, F. R., Canzar, S., Kaeuferle, T., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0793-1 · Cited by 42
The role of dendritic cells in cancer immunity and therapeutic strategies
Tai, Y., Chen, M., Wang, F., Fan, Y., Zhang, J., Cai, B., Lin, Y., Luo, Y., & Li, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111548 · Cited by 42
The Expression of Tim-3 in Peripheral Blood of Ovarian Cancer
Wu, J., Liu, C., Shao, Q., & Hou, H. (2013) · DNA and Cell Biology · doi:10.1089/dna.2013.2116 · Cited by 42
Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3).
Homayouni, V., Ganjalıkhani-Hakemi, M., Rezaei, A., Khanahmad, H., Behdani, M., & Kazemi‐Lomedasht, F. (2016) · PubMed Central · doi:10.22038/ijbms.2016.7820 · Cited by 41
Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study
Vaes, R. D. W., Reynders, K., Sprooten, J., Nevola, K. T., Rouschop, K. M. A., Vooijs, M., Garg, A. D., Lambrecht, M. L. F., Hendriks, L. E. L., Ručević, M., et al. (2021) · Cancers · doi:10.3390/cancers13246259 · Cited by 41
Contribution of dendritic cells to the autoimmune pathology of systemic lupus erythematosus
Mackern‐Oberti, J. P., Llanos, C., Riedel, C. A., Bueno, S. M., & Kalergis, A. M. (2015) · Immunology · doi:10.1111/imm.12504 · Cited by 42
TFAM is a novel mediator of immunogenic cancer cell death
Yang, M., Li, C., Zhu, S., Cao, L., Kroemer, G., Zeh, H. J., Tang, D., & Kang, R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1431086 · Cited by 41
On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment
Tundo, G. R., Sbardella, D., Lacal, P. M., Graziani, G., & Marini, S. (2019) · Chemotherapy · doi:10.1159/000500902 · Cited by 41
High-mobility group box 1 (HMGB1) in childhood: from bench to bedside
Chirico, V., Lacquaniti, A., Salpietro, V., Munafò, C., Calabrò, M. P., Buemi, M., Arrigo, T., & Salpietro, C. D. (2014) · European Journal of Pediatrics · doi:10.1007/s00431-014-2327-1 · Cited by 39
Malignant melanoma—The cradle of anti-neoplastic immunotherapy
Koller, K. M., Wang, W., Schell, T. D., Cozza, E. M., Kokolus, K. M., Neves, R. I., Mackley, H. B., Pameijer, C. R., Leung, A. M., Anderson, B. E., et al. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.04.010 · Cited by 40
Receptors That Inhibit Macrophage Activation: Mechanisms and Signals of Regulation and Tolerance
Ocaña‐Guzmán, R., Vazquez-Bolaños, L. A., & Sada‐Ovalle, I. (2018) · Journal of Immunology Research · doi:10.1155/2018/8695157 · Cited by 40
Phosphatidylserine receptor-targeting therapies for the treatment of cancer
Park, M., & Kang, K. W. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01167-4 · Cited by 39
Unleashing the power of immune checkpoints: Post-translational modification of novel molecules and clinical applications
Wang, J., Wang, Y., Jiang, X., Xu, M., Wang, M., Wang, R., Zheng, B., Chen, M., Qi, K., & Long, J. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216758 · Cited by 40
Membrane-bound heat shock proteins facilitate the uptake of dying cells and cross-presentation of cellular antigen
Zhu, H., Fang, X., Zhang, D., Wu, W., Shao, M., Wang, L., & Gu, J. (2015) · APOPTOSIS · doi:10.1007/s10495-015-1187-0 · Cited by 40
Bone marrow infiltrated Lnc-INSR induced suppressive immune microenvironment in pediatric acute lymphoblastic leukemia
Wang, Y., Yang, X., Sun, X., Rong, L., Kang, M., Wu, P., Ji, X., Lin, R., Huang, J., Xue, Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1078-8 · Cited by 38
The role of immune regulatory molecules in multiple sclerosis
Afshar, B., Khalifehzadeh-Esfahani, Z., Seyfizadeh, N., Danbaran, G. R., Hemmatzadeh, M., & Mohammadi, H. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.577061 · Cited by 38
Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment
Parodi, M., Pedrazzi, M., Cantoni, C., Averna, M., Patrone, M., Cavaletto, M., Spertino, S., Pende, D., Balsamo, M., Pietra, G., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1052353 · Cited by 38
The role of Tim-3 blockade in the tumor immune microenvironment beyond T cells
Zhang, J., Wang, L., Guo, H., Kong, S., Li, W., He, Q., Ding, L., & Yang, B. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107458 · Cited by 38
STAT3 and NF-κB are Simultaneously Suppressed in Dendritic Cells in Lung Cancer
Li, R., Fang, F., Jiang, M., Wang, C., Ma, J., Kang, W., Zhang, Q., Miao, Y., Wang, D., Guo, Y., et al. (2017) · Scientific Reports · doi:10.1038/srep45395 · Cited by 37
Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis
Wen, L., Lu, H., Li, Q., Li, Q., Wen, S., Wang, D., Wang, X., Fang, J., Cui, J., Cheng, B., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1185-0 · Cited by 38
Plasma levels of Galectin-9 reflect disease severity in malaria infection
Dembele, B. P. P., Yasutan, H. C., Niki, T., Ashino, Y., Tangpukdee, N., Shinichi, E., Krudsood, S., Kano, S., & Hattori, T. (2016) · Malaria Journal · doi:10.1186/s12936-016-1471-7 · Cited by 37
Influencing immunity: role of extracellular vesicles in tumor immune checkpoint dynamics
Ye, Z., Li, G., & Lei, J. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01340-w · Cited by 39
Translation of cancer immunotherapy from the bench to the bedside
Guo, Q., Huang, F., Gonçalves, C., Rincon, S. V. D., & Miller, W. H. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.001 · Cited by 35
TIM‐3 in normal and malignant hematopoiesis: Structure, function, and signaling pathways
Kikushige, Y. (2021) · Cancer Science · doi:10.1111/cas.15042 · Cited by 36
Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
Kuske, M., Haist, M., Jung, T., Grabbe, S., & Bros, M. (2022) · Cancers · doi:10.3390/cancers14071710 · Cited by 38
TIGIT signaling and its influence on T cell metabolism and immune cell function in the tumor microenvironment
Jantz-Naeem, N., Loschinski, R., Borucki, K., Mitchell-Flack, M., Böttcher, M., Schraven, B. L., Mougiakakos, D., & Kahlfuß, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1060112 · Cited by 37
Dialog beyond the Grave: Necrosis in the Tumor Microenvironment and Its Contribution to Tumor Growth
Zapletal, E., Vasiljević, T., Busson, P., & Glavan, T. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065278 · Cited by 41
Immunometabolic characteristics of Dendritic Cells and its significant modulation by mitochondria-associated signaling in the tumor microenvironment influence cancer progression
Ghosh, S., Dutta, R., Ghatak, D., Goswami, D., & De, R. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150268 · Cited by 35
Immune checkpoint inhibitors in infectious disease
King, H. A. D., & Lewin, S. R. (2024) · Immunological Reviews · doi:10.1111/imr.13388 · Cited by 35
Hepatitis C viral infection is associated with activated cytolytic natural killer cells expressing high levels of T cell immunoglobulin- and mucin-domain-containing molecule-3.
Golden‐Mason, L., Hurtado, C. W., Cheng, L., & Rosen, H. R. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.03.008 · Cited by 35
The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy
Yang, R., & Hung, M. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9176-7 · Cited by 35
Cancer Cells Resistance Shaping by Tumor Infiltrating Myeloid Cells
Domagala, M., Laplagne, C., Leveque, E., Laurent, C., Fournié, J., Espinosa, É., & Poupot, M. (2021) · Cancers · doi:10.3390/cancers13020165 · Cited by 36
Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer
Caro, A. A., Deschoemaeker, S., Allonsius, L., Coosemans, A., & Laoui, D. (2022) · Cancers · doi:10.3390/cancers14164037 · Cited by 36
Regulation of osteoclastogenesis through Tim-3: possible involvement of the Tim-3/galectin-9 system in the modulation of inflammatory bone destruction
Moriyama, K., Kukita, A., Li, Y.-J., Uehara, N., Zhang, J.-Q., Takahashi, I., & Kukita, T. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.107 · Cited by 35
Tumor-associated neutrophils upregulate PANoptosis to foster an immunosuppressive microenvironment of non-small cell lung cancer
Hu, Q., Wang, R., Zhang, J., Xue, Q., & Ding, B. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03564-7 · Cited by 34
Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma
Su, H., Xie, H., Dai, C., Ren, Y., She, Y., Xu, L., Chen, D., Xie, D., Zhang, L., Jiang, G., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.04.009 · Cited by 34
Discovery of New Immune Checkpoints: Family Grows Up
Kong, X. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_4 · Cited by 35
Fragment-Based Discovery of Small Molecules Bound to T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (TIM-3)
Rietz, T. A., Teuscher, K. B., Mills, J. J., Gogliotti, R. D., Lepovitz, L. T., Scaggs, W. R., Yoshida, K., Luong, K., Lee, T., & Fesik, S. W. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01336 · Cited by 35
Photophosphatidylserine Guides Natural Killer Cell Photoimmunotherapy via Tim-3
Yang, X., Li, M., Qin, X., Tan, S., Du, L., Ma, C., & Li, M. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c11498 · Cited by 35
Lipid Accumulation in Peripheral Blood Dendritic Cells and Anticancer Immunity in Patients with Lung Cancer
Arai, R., Soda, S., Okutomi, T., Morita, H., Ohmi, F., Funakoshi, T., Takemasa, A., & Ishii, Y. (2018) · Journal of Immunology Research · doi:10.1155/2018/5708239 · Cited by 34
Dismantlable Coronated Nanoparticles for Coupling the Induction and Perception of Immunogenic Cell Death
Liang, H., Xu, C., Guo, D., Peng, F., Chen, N., Song, H., & Ji, X. (2024) · Advanced Materials · doi:10.1002/adma.202313097 · Cited by 33
Cooperation between inhibitory immune checkpoints of senescent cells with immunosuppressive network to promote immunosenescence and the aging process
Salminen, A. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102694 · Cited by 33
Neutrophils, Dendritic Cells, Toll-Like Receptors, and Interferon-α in Lupus Nephritis
Lorenz, G., & Anders, H. (2015) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2015.08.003 · Cited by 33
Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors
Nie, Y., Yang, D., Trivett, A. L., Han, Z., Xin, H., Chen, X., & Oppenheim, J. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-14655-8 · Cited by 33
Ligation of free HMGB1 to TLR2 in the absence of ligand is negatively regulated by the C-terminal tail domain
Aucott, H., Sowińska, A., Harris, H. E., & Lundbäck, P. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0021-x · Cited by 34
Complement inhibition ameliorates blast-induced acute lung injury in rats: Potential role of complement in intracellular HMGB1-mediated inflammation
Li, Y., Yang, Z., Chavko, M., Liu, B., Aderemi, O. A., Simovic, M. O., Dubick, M. A., & Cancio, L. C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202594 · Cited by 33
The Role of Immunomodulatory Receptors in the Pathogenesis of HIV Infection: A Therapeutic Opportunity for HIV Cure?
Chen, H., Moussa, M., & Catálfamo, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01223 · Cited by 33
Ratiometric Fluorescence Imaging for the Distribution of Nucleic Acid Content in Living Cells and Human Tissue Sections
Liu, L., Zhao, Y., Zhang, N., Wang, K., Tian, M., Pan, Q., & Lin, W. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c04064 · Cited by 33
Early‐Responsive Immunoregulation Therapy Improved Microenvironment for Bone Regeneration Via Engineered Extracellular Vesicles
Lu, T., Liu, Y., Huang, X., Sun, S., Xu, H., Jin, A., Wang, X., Gao, X., Liu, J., Zhu, Y., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202303681 · Cited by 32
NK cell receptors in anti-tumor and healthy tissue protection: Mechanisms and therapeutic advances
Greppi, M., Franco, F. D., Obino, V., Rebaudi, F., Goda, R., Frumento, D., Vita, G., Baronti, C., Melaiu, O., Bozzo, M., et al. (2024) · Immunology Letters · doi:10.1016/j.imlet.2024.106932 · Cited by 32
Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms
Sun, L., Chen, L., & Li, H. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.12.006 · Cited by 34
Control of Regulatory T Cells by Co-signal Molecules
Wing, J. B., Tay, C., & Sakaguchi, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_7 · Cited by 32
Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside
Ghorbaninezhad, F., Asadzadeh, Z., Masoumi, J., Mokhtarzadeh, A., Kazemi, T., Maleki, L. A., Shotorbani, S. S., Shadbad, M. A., Baghbanzadeh, A., Hemmat, N., et al. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120466 · Cited by 34
Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies
Zhao, L.-P., Hu, J.-H., Hu, D., Wang, H., Huang, C.-G., Luo, R., Huang, X., Huang, X., Xie, T., & Lou, J.-S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112949 · Cited by 34
In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways
Abdeladhim, M., Karnell, J. L., & Rieder, S. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1033705 · Cited by 32
Cutting Edge: Anti–TIM-3 Treatment Exacerbates Pulmonary Inflammation and Fibrosis in Mice
Isshiki, T., Akiba, H., NAKAYAMA, M., Harada, N., Okumura, K., Homma, S. A., & Miyake, S. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700059 · Cited by 32
Self-citation
HMGB1 Signaling-Mediated Tumor Immunity in Cancer Progress
Wen, J., & Zhang, X. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2810260 · Cited by 31
Immune checkpoint receptors in cancer: redundant by design?
Li, J., Ni, L., & Dong, C. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.01.001 · Cited by 31
Exploiting tumor-associated dendritic cell heterogeneity for novel cancer therapies
Keirsse, J., Damme, H. V., Ginderachter, J. A. V., & Laoui, D. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.4mr1116-466r · Cited by 31
Tim-3 exacerbates kidney ischaemia/reperfusion injury through the TLR-4/NF-κB signalling pathway and an NLR-C4 inflammasome activation
Guo, Y., Zhang, J., Lai, X., Chen, M., & Guo, Y. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13126 · Cited by 32
Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer
Wang, F., Yang, M., Luo, W., & Zhou, Q. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.10.002 · Cited by 33
Dendritic Cell-Targeted Approaches to Modulate Immune Dysfunction in the Tumor Microenvironment
Gallois, A., & Bhardwaj, N. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00436 · Cited by 32
HMGB1: a double-edged sword and therapeutic target in the female reproductive system
Ren, Y., Zhu, D., Han, X., Zhang, Q., Chen, B., Zhou, P., Wei, Z., Zhang, Z., Cao, Y., & Zou, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1238785 · Cited by 30
Negative regulation of Nod‐like receptor protein 3 inflammasome activation by T cell Ig mucin‐3 protects against peritonitis
Wang, W., Shi, Q., Dou, S., Li, G., Shi, X., Jiang, X., Wang, Z., Yu, D., Chen, G., Wang, R., et al. (2017) · Immunology · doi:10.1111/imm.12812 · Cited by 30
Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1)
Raggi, F., & Bosco, M. C. (2020) · Cancers · doi:10.3390/cancers12051337 · Cited by 30
Unexplored horizons of cDC1 in immunity and tolerance
Balan, S., Radford, K. J., & Bhardwaj, N. (2020) · Advances in immunology · doi:10.1016/bs.ai.2020.10.002 · Cited by 34
Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: A narrative review
Liu, Y., Zhang, Z., Wang, S., Fu, S., Cheng, X., Chen, R., & Sun, T. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108900 · Cited by 31
Expansion of Dysfunctional Tim-3–Expressing Effector Memory CD8+ T Cells during Simian Immunodeficiency Virus Infection in Rhesus Macaques
Fujita, T., Burwitz, B. J., Chew, G. M., Reed, J. S., Pathak, R., Seger, E., Clayton, K., Rini, J. M., Ostrowski, M., Ishii, N., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400961 · Cited by 30
The impact of the TIM gene family on tumor immunity and immunosuppression
Baghdadi, M., & Jinushi, M. (2013) · Cellular and Molecular Immunology · doi:10.1038/cmi.2013.57 · Cited by 30
Self-citation
Stimulation through CD40 and TLR-4 Is an Effective Host Directed Therapy against Mycobacterium tuberculosis
Khan, N., Pahari, S., Vidyarthi, A., Aqdas, M., & Agrewala, J. N. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00386 · Cited by 30
TIM‐3: An emerging target in the liver diseases
Zhao, L., Yu, G., Han, Q., Cui, C., & Zhang, B. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12825 · Cited by 30
Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies
Roussot, N., Kaderbhaï, C., & Ghiringhelli, F. (2025) · Cancers · doi:10.3390/cancers17050906 · Cited by 29
A 175 Million Year History of T Cell Regulatory Molecules Reveals Widespread Selection, with Adaptive Evolution of Disease Alleles
Forni, D., Cagliani, R., Pozzoli, U., Colleoni, M., Riva, S., Biasin, M., Filippi, G., GIOIA, L. D., Gnudi, F., Comi, G. P., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.04.008 · Cited by 29
Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma
Elia, A. R., Caputo, S., & Bellone, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01786 · Cited by 30
High Mobility Group Box 1 (HMGB1) Induces Toll-Like Receptor 4-Mediated Production of the Immunosuppressive Protein Galectin-9 in Human Cancer Cells
Selnø, A. T. H., Schlichtner, S., Yasinska, I. M., Sakhnevych, S. S., Fiedler, W., Wellbrock, J., Berger, S., Klenova, E. M., Gibbs, B. F., Fasler‐Kan, E., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.675731 · Cited by 29
AllergoOncology: Role of immune cells and immune proteins
Gioacchino, M. D., Valle, L. D., Allegra, A., Pioggia, G., & Gangemi, S. (2022) · Clinical and Translational Allergy · doi:10.1002/clt2.12133 · Cited by 30
Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
Catalano, M., Shabani, S., Venturini, J., Ottanelli, C., Voltolini, L., & Roviello, G. (2022) · Cancers · doi:10.3390/cancers14246145 · Cited by 29
Unveiling the immune symphony: decoding colorectal cancer metastasis through immune interactions
He, R., Huang, S., Lu, J., Su, L., Gao, X., & Chi, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1362709 · Cited by 29
Regulation of T cell trafficking by the T cell immunoglobulin and mucin domain 1 glycoprotein
Angiari, S., & Constantin, G. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.10.003 · Cited by 31
Tumor Microenvironment Drives the Cross-Talk Between Co-Stimulatory and Inhibitory Molecules in Tumor-Infiltrating Lymphocytes: Implications for Optimizing Immunotherapy Outcomes
Franzese, O. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312848 · Cited by 29
TIM-3 Expression Is Downregulated on Human NK Cells in Response to Cancer Targets in Synergy with Activation
Dao, T. N., Utturkar, S. M., Lanman, N. A., & Matosevic, S. (2020) · Cancers · doi:10.3390/cancers12092417 · Cited by 29
Infection and cancer suppress pDC derived IFN-I
Greene, T. T., Jo, Y., & Zúñiga, E. I. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.08.001 · Cited by 28
Single-cell immune checkpoint landscape of PBMCs stimulated with Candida albicans
Deng, W., Su, Z., Liang, P., Ma, Y., Liu, Y., Zhang, K., Zhang, Y., Liang, T., Shao, J., Liu, X., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1942228 · Cited by 28

Authors: Chiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dosaka-Akita, H., Fujioka, Y., Ohba, Y., Gorman, J. V., Colgan, J. D., Hirashima, M., Uede, T., Takaoka, A., Yagita, H., & Jinushi, M.
Affiliations: Hokkaido University (JP)
Juntendo University (JP)
University of Iowa (US)
Kagawa University (JP)
Corresponding author: Jinushi, Masahisa
ORCID: Baghdadi, Muhammad
Akiba, Hisaya
Yoshiyama, Hironori
Kinoshita, Ichiro
Fujioka, Yoichiro
Ohba, Yusuke
Colgan, John D
Hirashima, Mitsuomi
Takaoka, Akinori
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2012-07-29
Volume: 13
Issue: 9
Pages: 832-842
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/ni.2376
PMC: PMC3622453
OpenAlex: W2112400160
Cited by: 838
References: 50
Citations by year: 2026: 40 · 2025: 53 · 2024: 81 · 2023: 82 · 2022: 83 · 2021: 80 · 2020: 65 · 2019: 63 · 2018: 56 · 2017: 48 · 2016: 53 · 2015: 41 · 2014: 39 · 2013: 39 · 2012: 15
FWCI: 18.74
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Institutional Repositories DataBase (IRDB) (submittedVersion)
Hokkaido University Collection of Scholarly and Academic Papers (Hokkaido University) (submittedVersion)
Funders: Japan Society for the Promotion of Science (23590534, 23591132, 23501283, 22590360, 23390090, 22591098, 22240089, 23659196, 21390113)
National Institute of Allergy and Infectious Diseases (R01AI093737, R01AI067489)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: TIM-3, HMGB1, tumor-associated dendritic cells, nucleic acid sensing, innate immunity, tumor microenvironment, Toll-like receptors, galectin-9, DNA vaccine, chemotherapy, antitumor immunity, alarmins
MeSH terms: Hepatitis A Virus Cellular Receptor 2, Animals, Dendritic Cells, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Humans, Immunity, Innate, Immunologic Surveillance, Mice, Inbred C57BL, Microscopy, Fluorescence, Neoplasms, Nucleic Acids, Receptors, Virus, Immunoblotting, Microscopy, Confocal, Reverse Transcriptase Polymerase Chain Reaction, HMGB1 Protein, Receptors, Pattern Recognition, Mice, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks